Treatment-Associated changes in serum glial fibrillary acidic protein and neurofilament light chain levels and risk of disability progression independent of relapse activity in multiple sclerosis

Authors
Category Primary study
ConferenceThe 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Year 2024
This article has no abstract
Epistemonikos ID: 5cada6aa0f9c0f4607f20e13c05336d5150e9401
First added on: Apr 04, 2026